Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 188 of 5804
-
Can a cancer drug reboot the immune system in chronic fatigue syndrome?
Disease control Not yet recruitingPost-acute infection syndromes (PAIS) are long-lasting health problems that can develop after an infection. They include post-COVID-19 syndrome and similar illnesses following other infections. Some people with PAIS develop myalgic encephalomyelitis/chronic fatigue syndrome (ME/C…
Phase: PHASE2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for FSGS: experimental drug APL2 enters Late-Stage trial
Disease control TerminatedThis is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior t…
Phase: PHASE2, PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Virtual reality and glowing dye could make lung cancer surgery safer
Disease control Not yet recruitingWith the advent of CT screening for lung cancer, an increasing number of NSCLCs are being detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly. As such, there is a need to develop new surgical techniques to facilitate minimally invasive pulm…
Phase: PHASE1, PHASE2 • Sponsor: St. Joseph's Healthcare Hamilton • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Sponge on a string and AI could revolutionize esophageal cancer screening
Diagnosis Not yet recruitingThis clinical trial studies how well minimally invasive approaches (an artificial intelligence \[AI\] powered risk tool, nurse navigation, and a sponge on a string \[SOS\] test) work in diagnosing patients with Barrett's esophagus (BE) and esophageal cancer. Esophageal cancer has…
Phase: NA • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Low-Dose erlotinib aims to stop liver cancer before it starts
Prevention Not yet recruitingThis phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to preserve sight in rare genetic blindness
Disease control Not yet recruitingThe goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the…
Phase: PHASE3 • Sponsor: Nacuity Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Balloon in the womb: new hope for babies with underdeveloped lungs?
Disease control Recruiting nowThe purpose of this research is to gather information on the safety and effectiveness of a procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO) at Mayo Clinic. The intent of the FETO procedure is to improve development of the lungs in fetuses diagnosed with severe co…
Phase: NA • Sponsor: Mauro H. Schenone • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill aims to keep leukemia away after transplant
Disease control Not yet recruitingRevumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to …
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Hope for sanfilippo kids: Brain-Infused drug enters final testing
Disease control Not yet recruitingThe primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition
Phase: PHASE3 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New 5-Drug cocktail aims to tackle High-Risk myeloma
Disease control Not yet recruitingThis study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem …
Phase: PHASE1, PHASE2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Radiation and immunotherapy team up against hard-to-treat lymphoma
Disease control Not yet recruitingThe goal of this clinical trial is to see if a new combination of standard of care radiotherapy treatment prior to administering the study drugs obinutuzumab and glofitamab in relapsed/refractory Diffuse Large B Cell Lymphoma patients is effective. The main question it aims to an…
Phase: PHASE2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Zapping the heart back to rhythm: a new device uses pulsed fields to treat atrial fibrillation
Disease control Not yet recruitingThis study will evaluate the long-term safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal atrial fibrillation.
Phase: NA • Sponsor: Kardium Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy aims to tackle tough pancreatic tumors
Disease control Not yet recruitingThe purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable.
Phase: PHASE1 • Sponsor: Haoming (Carl) Qiu • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Major trial pits drugs vs. surgery vs. stents for failing hearts
Disease control TerminatedThe ISCHEMIA-HF trial will randomize participants with multivessel coronary artery disease (CAD) with ejection fraction (EF) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (GDMT):coronary artery bypass grafting (CABG):percutaneous coronary intervention (PCI).
Phase: PHASE3 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New cocktail of drugs takes on Hard-to-Treat bladder cancer
Disease control Not yet recruitingThis phase Ib/II trial tests the safety, side effects, and best dose of quemliclustat in combination with enfortumab vedotin and pembrolizumab, and to see how well the combination works for the treatment of bladder, renal pelvis, or ureter urothelial cancer that cannot be removed…
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Eye injection aims to clear fluid in chronic vision disorder
Disease control Not yet recruitingDysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated n…
Phase: PHASE2 • Sponsor: Singapore National Eye Centre • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Spinal cord cell transplant aims to slow ALS
Disease control Not yet recruitingThis study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects with ALS. Following an initial cohort receiving cell…
Phase: PHASE1, PHASE2 • Sponsor: Q Therapeutics, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Blood test could tell doctors when to stop prostate cancer treatment early
Disease control Not yet recruitingThis clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostat…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail aims to tame tough leukemias
Disease control Not yet recruitingThe goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets rare, aggressive skin cancer after chemotherapy fails
Disease control Not yet recruitingThis is a pilot study evaluating the efficacy and safety of ivonescimab in subjects with advanced or metastatic cutaneous angiosarcoma who have previously been treated with taxane-based chemotherapy.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC